Ahmedabad: Zydus Cadila on Friday announced the launch of Tenglyn – Teneligliptin 20 mg tablets, which belongs to a new class of oral anti-diabetic agents, Gliptins.
With an aim to make this therapy affordable and accessible to diabetic patients, Tenglyn is being priced at Rs 7 per tablet, which is almost 1/6th the price at which the Gliptins were initially launched in India, Zydus said in a statement.
Gliptins have shown promise in achieving glycaemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management.
Research in the field of anti-diabetic therapy seeks to address the problems of hypoglycaemia, gastrointestinal side effects, lactic acidosis, weight gain, cardiovascular risks etc, which pose a major challenge in the treatment of diabetes.
Sharvil Patel, deputy managing director, Zydus Cadila, said, “Diabetes, as we know, is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost.”
The incidence of diabetes is an alarming one with the number of diabetics in the world estimated to be over 360 million. With a patient population of almost 65 million diabetics in India, access to affordable therapy is critical.
The launch of Tenglyn comes as a boon and will help a large number of patients in India suffering from Type II diabetes, access the affordable gliptin therapy, the statement said.